Mizuho Maintains Buy on Vaxcyte, Raises Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and increased the price target from $69 to $113, indicating a positive outlook on the company's stock.
March 12, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Salim Syed has reaffirmed a Buy rating on Vaxcyte and raised the price target from $69 to $113, suggesting a strong confidence in the company's future performance.
The increase in price target by a reputable analyst like Salim Syed from Mizuho signals a strong vote of confidence in Vaxcyte's potential. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100